The study helps explain how cancer cells adapt and tolerate treatment and identify combination therapies to improve outcomes in people.

To take advantage of these new therapies, people must first learn whether their cancer harbors targetable mutations.

MRTX849 shrank tumors in half of lung cancer patients with a common but difficult to target mutation.

First KRAS targeted therapy shows promise for lung and colon cancer

Half of study participants treated with AMG 510 saw their tumors shrink, and only one experienced disease progression.

This held true regardless of whether statins were taken before or after the cancer diagnosis.

Three independent studies suggest a way to thwart a mutated gene that drives tumor growth in 95 percent of people with the disease.

Approach prevents cancers from making proteins they need to grow and to evade the immune system, while leaving healthy cells unharmed.

Cancer today feels like AIDS in the mid-1990s.